In 2008, Time magazine named genetic testing company 23andMe and its at-home DNA testing kit the Invention of the Year. Eventually, about 15 million people signed up for it. Sixteen years later and ...

23andMe announced on March 24 that it had filed for chapter 11 bankruptcy, leaving customers wondering what will happen with the data the company has collected. A court-supervised sale will determine ...

23andMe filed for Chapter 11 bankruptcy on Sunday. The company says no changes will be made to how it stores, manages or protects customer data up until the sale of its assets is finalized. 23andMe ...

23andMe filed for bankruptcy, proposing to try to sell all of its assets. For consumers who have provided genetic data to the company for testing purposes, here’s what to know: The DNA-testing company ...

23andMe’s interim chief executive Joseph Selsavage told lawmakers on Tuesday that 1.9 million people, or about 15% of its customer base, have requested their genetic data be deleted from the company’s ...

23andMe has filed for Chapter 11 bankruptcy protection and its co-founder and CEO has resigned as the struggling genetic testing company continues its push to cut costs. Bay Area-based 23andMe ...

23andMe's database is shrinking as customers request to delete their data. Interim CEO Joseph Selsavage said 1.9 million customers have asked for data deletions. 23andMe said its business could be ...

Ancestry company 23andMe agreed to settle a multi-million class action lawsuit that accused it of not protecting its users’ data. The company announced a year ago that hackers had breached its systems ...

Kayte Spector-Bagdady, is an associate professor of obstetrics and gynecology at the University of Michigan. As soon as the genetic testing company 23andMe filed for bankruptcy on March 23, 2025, ...

A court hearing to consider the transaction’s approval is scheduled for June 17, according to 23andMe Justin Sullivan/Getty; Michael Nagle/Bloomberg via Getty Genetics company 23andMe is expected to ...

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest ...